Axel Grothey
阿克塞尔·格罗泰
MD
Director of GI Oncology, West Cancer Center & Research Institute; Professor of Medicine, University of Tennessee Health Science Center西部癌症中心胃肠道肿瘤学主任；田纳西大学健康科学中心医学教授
👥Biography 个人简介
Axel Grothey, MD is Director of GI Oncology at the West Cancer Center & Research Institute in Memphis and Professor of Medicine at the University of Tennessee Health Science Center. Previously on staff at Mayo Clinic for more than a decade, he is among the most influential clinical investigators in colorectal cancer worldwide, with landmark contributions spanning chemotherapy optimization, targeted therapy, and the concept of treatment continuum. Dr. Grothey served as the global principal investigator of the CORRECT trial, the pivotal phase III study establishing regorafenib — the first oral multikinase inhibitor — as a new standard for chemotherapy-refractory metastatic CRC, prolonging overall survival compared to placebo and securing FDA and EMA approval. He was also the principal investigator of the ANCHOR-CRC trial evaluating triplet BRAF/MEK/EGFR inhibition (encorafenib + binimetinib + cetuximab) as first-line therapy in BRAFV600E-mutant mCRC. Dr. Grothey is also known for the OPTIMOX trials defining chemotherapy-free intervals and bevacizumab maintenance, and for studies on the clinical value of continuing bevacizumab beyond progression (TML/ML18147 analysis). He has authored more than 300 peer-reviewed papers and is a past member of the ASCO board of directors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CORRECT Trial — Regorafenib as First Approved Refractory mCRC Agent
Served as global principal investigator of the CORRECT phase III trial demonstrating that regorafenib significantly improved overall survival (6.4 vs 5.0 months) versus placebo in heavily pretreated refractory metastatic CRC — representing the first oral targeted agent to demonstrate survival benefit in this setting — leading to FDA approval in 2012 and establishing a new treatment option for patients who have exhausted standard chemotherapy.
ANCHOR-CRC — First-Line Triplet Targeted Therapy for BRAFV600E mCRC
Led the ANCHOR-CRC phase II trial evaluating encorafenib plus binimetinib plus cetuximab (triplet) as first-line therapy for BRAFV600E-mutant metastatic CRC, demonstrating an objective response rate of 47.8% and median PFS of 5.8 months in a population historically characterized by very poor prognosis on chemotherapy, contributing key data informing first-line BRAF-targeted treatment investigation.
Bevacizumab Beyond Progression — TML/ML18147 Analysis
Contributed critical analyses of the TML (ML18147) trial and related studies demonstrating that continuing bevacizumab beyond first-line progression while switching chemotherapy backbone provides a modest but statistically significant survival benefit in metastatic CRC, a strategy subsequently incorporated into ESMO and NCCN guidelines as an acceptable second-line approach.
Treatment Continuum Concept and OPTIMOX Chemotherapy-Free Intervals
Championed the "treatment continuum" concept in metastatic CRC, demonstrating through multiple analyses that patients who receive all active agents (oxaliplatin, irinotecan, bevacizumab, anti-EGFR) over the course of their disease derive superior overall survival, and contributed to OPTIMOX-based evidence supporting chemotherapy-free maintenance intervals to reduce cumulative toxicity while preserving efficacy.
Representative Works 代表性著作
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)
The Lancet (2013)
CORRECT phase III trial establishing regorafenib as the first approved oral targeted agent for refractory metastatic CRC with significantly improved overall survival versus placebo.
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON-CRC study
Journal of Clinical Oncology (2021)
Updated BEACON CRC analysis confirming encorafenib plus cetuximab survival benefit across subgroups in BRAFV600E-mutant mCRC, with median OS of 9.3 months versus 5.9 months for control.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
New England Journal of Medicine (2009)
CALGB/SWOG 80405 analysis contributions examining concurrent anti-VEGF and anti-EGFR therapy in RAS wild-type and unselected metastatic CRC populations.
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
Journal of Clinical Oncology (2004)
Landmark analysis demonstrating that exposure to all three active drug classes (5-FU, irinotecan, oxaliplatin) over the disease course correlates with superior overall survival, establishing the treatment-continuum paradigm in mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 阿克塞尔·格罗泰 的研究动态
Follow Axel Grothey's research updates
留下邮箱，当我们发布与 Axel Grothey（West Cancer Center & Research Institute, Memphis）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment